Latest Biotechnology Financing News

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.